PREVALENCE AND STRUCTURE OF HIV-1 DRUG RESISTANCE AMONG TREATMENT NAÏVE PATIENTS SINCE THE INTRODUCTION OF ANTIRETROVIRAL THERAPY IN THE RUSSIAN FEDERATION

Aim: to analyze the prevalence, structure of drug resistance and drug resistance mutations in the protease and reverse transcriptase genes of HIV-1 among treatment naïve patients.

Materials and methods. We analyzed protease and reverse transcriptase sequences from 1560 treatment naïve HIV-infected patients from all Federal Districts of the Russian Federation with the first positive immune blot during 1998–2017. Sequences were analyzed for the presence of drug resistance mutations and predicted drug resistance to antiretroviral drugs using two algorithms — Stanford HIVDR Database (HIVdb) and the 2009 SDRM list (CPR).

Results. The prevalence of drug resistance mutations was 11,1%. More often the prevalence of drug resistance was found for non-nucleoside reverse transcriptase inhibitor drugs (rilpivirine, nevirapine, efavirenz). The prevalence of transmitted drug resistance associated with mutations from the SDRM list was 5,3%, which is classified by the WHO as a moderate level. However, it should be noted that since the large-scale use of antiretroviral drugs in the Russian Federation, there has been a trend towards a gradual increase in the level of the transmitted drug resistance, and in 2016 it has already reached 6,1%.

Conclusion. The results demonstrate the need for regular surveillance of the prevalence of HIV drug resistance to antiretroviral drugs among treatment naïve patients in the Russian Federation.

1. Joint United Nations Programme (UNAIDS). 90-90-90 An ambitious treatment target to help end the AIDS epidemic. Geneva, 2014, 33 p. URL: http://www.unaids.org/sites/default/files/media_asset/90-90-90_en_0.pdf (October 2014).

2. Guidelines on the public health response to pretreatment HIV drug resistance. Geneva: World Health Organization, 2017, 84 p. URL: https://apps.who.int/iris/bitstream/handle/10665/255880/9789241550055-eng.pdf?sequence=1 (July 2017).

3. WHO/HIVResNet HIV drug resistance laboratory operational framework. Geneva: World Health Organization, 2017, 73 p. URL: https://apps.who.int/iris/bitstream/handle/10665/259731/9789241512879-eng.pdf?sequence=1 (December 2017).

4. Fokam J., Takou D., Santoro M.M., Akonie H.Z., Kouanfack C., Ceccherini-Silberstein F., Colizzi V. et al. Population-based surveillance of HIV- 1 drug resistance in Cameroonian adults initiating antireviral therapy according to the World Health Organization guidelines. AIDS Res. Hum. Retrovir., 2016, Vol. 32, No. 4, pp. 329–333.

5. Quinn T.C. HIV epidemiology and the effects of antiviral therapy on long-term consequences. AIDS, 2008, Vol. 22, Suppl. 3, pp. S7–S12.

6. Ладная Н.Н., Богословская Е.В., Суханова А.Л. и др. Распространенность штаммов ВИЧ, резистентных к антиретровирусным препаратам, передающихся от пациента к пациенту на территории шести субъектов России // Сб. трудов 6-й Всероссийской научно-практической кон- ференции с международным участием «Молекулярная диагностика — 2007». 2007. Т. 1. С. 121–123. [Ladnaya N.N., Bogoslovskaya E.V., Suhanova A.L. et al. The prevalence of HIV strains resistant to antiretroviral drugs, transmitted from patient to patient in the territory of six subjects of Russia. Proceedings of the 6th All-Russian Sientific-Practical Conference with international participation «Molecular Diagnostics — 2007», 2007, Vol. 1, pp. 121–123 (In Russ.)].

7. Зайцева Н.Н., Парфенова О.В., Пекшева О.Ю. Анализ распространенности первичной резистентности ВИЧ к антиретровирусным препаратам в Приволжском федеральном округе // Медицинский альманах. 2016. T. 3, № 43. С. 93–95. [Zaytseva N.N., Parfenova O.V., Peksheva O.Yu. Analysis of the prevalence of primary resistance of HIV to antiretroviral drugs in the Volga Federal District. Medical almanac, 2016, Vol. 3, No. 43, pp. 148–151 (In Russ.)].

8. Lapovok I., Murzakova A., Lopatukhin A., Kireev D., Kazennova E., Bobkova M. et al. Prevalence of HIV-1 drug resistance mutations among ART-naive patients in Russia from 2005 to 2015. Proceedings of 14th European Meeting on HIV & Hepatitis. Rev. Antivir. Ther. Infect. Dis., 2016, Vol. 4, pp. 83–84.

9. Дементьева Н.Е., Сизова Н.В., Лисицина З.Н., Маклакова В.А., Крутицкая Л.И., Беляков Н.А. Анализ субтипов и фармакорезистентных вариантов ВИЧ, циркулирующих среди ВИЧ-инфицированных пациентов Санкт-Петербурга // ВИЧ-инфекция и иммуносупрессии. 2011. T. 3, № 4. C. 34–43. [Dement’eva N.Ye., Sizova N.V., Lisitsyna Z.N., Maklakova V.A., Krutitskaya L.I., Belyakov N.A. Analysis of HIV subtypes and dru-resistant variants circulating in Saint-Petersburg. HIV Infection and Immunosuppressive Disorders, 2011, Vol. 3, No. 4, pp. 34–43 (In Russ.)].

10. Bennett D.E., Camacho R.J., Otelea D. et al. Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009. PLoS One, 2009, Vol. 4, No. 3, pp. 1–8 (e4724).

11. Foley B.T., Leitner T., Paraskevis D., Peeter M. Primate immunodeficiency virus classification and nomenclature. Infect. Genet. Evol., 2016, pp. 150–158.

12. Казеннова Е.В., Лаповок И.А., Лага В.Ю., Васильев А.В., Бобкова М.Р. Естественные полиморфизмы гена pol варианта ВИЧ-1 IDU-A // ВИЧ-инфекция и иммуносупрессии. 2012. Т. 4, № 4. С. 44–51. [Kazennova E.V., Lapovok I.A., Laga V.Yu., Vasilyev A.V., Bobkova M.R. Natural polymorphisms of HIV-1 IDU-A variant pol gene. HIV Infection and Immunosuppressive Disorders, 2012, Vol. 4, No. 4, pp. 44–51 (In Russ.)].

13. Покровская А.В., Козырина Н.В., Гущина Ю.Ш., Юрин О.Г., Суворова З.К., Покровский В.В. Социально-демографический портрет пациента, живущего с ВИЧ и посещающего центры СПИД в России // Терапевтический архив. 2016. Т. 88, № 11. С. 12–16. [Pokrovskaya A.V., Kozyrina N.V., Gushchina Yu.Sh., Yurin O.G., Suvorova Z.K., Pokrovsky V.V. Socio-demographic portrait of a patient living with HIV who visits AIDS centers in Russia. Therapeutic archive, 2016, Vol. 88, No. 11, pp. 12–16 (In Russ.)].

14. Bennett D.E., Myatt M., Bertagnolio S., Sutherland D., Gilks C.F. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir. Ther., 2008, Vol. 13, Suppl. 2, pp. 25–36.